Status:
RECRUITING
Topotecan and Melphalan for Retinoblastoma
Lead Sponsor:
Sun Yat-sen University
Conditions:
Retinoblastoma
Chemotherapy Effect
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Detailed Description
To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.
Eligibility Criteria
Inclusion
- diagnosed as retinoblastoma
- receiving eyeball-sparing treatment
Exclusion
- disease progression during follow-up
Key Trial Info
Start Date :
March 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04799002
Start Date
March 11 2021
End Date
December 30 2027
Last Update
March 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University
Guangzhou, Guangdong, China, 510000